The FDA recently approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis. Zinbryta is a long-acting subcutaneous injection that is administered once a month. Zinbryta has shown efficacy in two large clinical trials, one of which compared this drug to Avonex. There are additional safety concerns with this medication, however, including possible damage to the liver. Patients on Zinbryta will have to perform blood tests to monitor liver function prior to starting the treatment, monthly before each dose, and for up to six months after the last dose. The choice of MS treatment is complex and many factors including efficacy, safety, and tolerability are considered for each patient on an individual basis. Patients should discuss their MS treatments with their IMSMP neurologist at each office visit.